3351 - 3360 of 8404 Results
Title
Year
- Expanding sexual and gender minority research in movement disorders: More than awareness and acceptance2021RESTRICTEDTitle: Expanding sexual and gender minority research in movement disorders: More than awareness and acceptanceJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 162End Page: 165Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.05.019Citation Count: 13
-
OPENTitle: Focused WorkshopsJournal Name: European Journal of NeurologyPublisher: WileyVol: 28Issue #: S1Start Page: 23End Page: 43Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1111/ene.14970Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14970Citation Count: 0
-
RESTRICTEDTitle: Parkinson's diseaseJournal Name: The LancetPublisher: Elsevier BVVol: 397Issue #: 10291Start Page: 2284End Page: 2303Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(21)00218-xBest OA location URL: https://repository.ubn.ru.nl//bitstream/handle/2066/235670/235670.pdfCitation Count: 1391
-
OPENTitle: Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016Best OA location URL: https://discovery.ucl.ac.uk/10129543/3/Zetterberg_Pilotto.pdfCitation Count: 40
- Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study2021OPENTitle: Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 StudyJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 11Issue #: 3Start Page: 1079End Page: 1089Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212594Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212594?id=journal-of-parkinsons-disease%2Fjpd212594Citation Count: 47
-
RESTRICTEDTitle: The emerging landscape of single-molecule protein sequencing technologiesJournal Name: Nature MethodsPublisher: Springer Science and Business Media LLCVol: 18Issue #: 6Start Page: 604End Page: 617Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41592-021-01143-1Best OA location URL: https://www.nature.com/articles/s41592-021-01143-1.pdfCitation Count: 204
-
OPENTitle: The Records of the Human Sciences Research CouncilJournal Name: History in AfricaPublisher: Cambridge University Press (CUP)Vol: 48Issue #:Start Page: 397End Page: 411Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1017/hia.2021.15Citation Count: 1
- Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney2021RESTRICTEDTitle: Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in SydneyJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: 1Start Page: 178End Page: 190Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/alz.12380Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.12380Citation Count: 6
- Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis2021OPENTitle: Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosisJournal Name: Journal of Managed Care & Specialty PharmacyPublisher: Academy of Managed Care PharmacyVol: 27Issue #: 6Start Page: 785End Page: 790Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.18553/jmcp.2021.27.6.785Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391001Citation Count: 10
- Development and evaluation of [18F]Flotaza for Aβ plaque imaging in postmortem human Alzheimer’s disease brain2021OPENTitle: Development and evaluation of [18F]Flotaza for Aβ plaque imaging in postmortem human Alzheimer’s disease brainJournal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 46Issue #:Start Page: 128164End Page: 128164Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2021.128164Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379902Citation Count: 15